Evidence map›Paper›PMID 39239160›Full record

ArticlePublic health action2024

TB-related technical enquiries received at the Research Institute of Tuberculosis, Japan, during COVID-19.

M Urakawa, A Yasukawa, S Hirao, M Ota, Y Hatamoto, T Zama, Y Nagata, T Yoshiyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health action, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M UrakawaResearch Institute of Tuberculosis, Tokyo, Japan.
A YasukawaResearch Institute of Tuberculosis, Tokyo, Japan.
S HiraoResearch Institute of Tuberculosis, Tokyo, Japan.
M OtaResearch Institute of Tuberculosis, Tokyo, Japan.
Y HatamotoResearch Institute of Tuberculosis, Tokyo, Japan.
T ZamaResearch Institute of Tuberculosis, Tokyo, Japan.
Y NagataResearch Institute of Tuberculosis, Tokyo, Japan.
T YoshiyamaResearch Institute of Tuberculosis, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

settingJapan: a low-TB-burden country.

objectiveTo characterise TB-related technical enquiries received in 2020-2022, and share the lessons learnt.

designThis was a descriptive study.

resultsWe received 1,898 communications, of which 1,447 (40.2 per month) were classified as technical enquiries, 34% fewer than the 2,197 enquiries received in 2017-2019. The enquiry rates were highest for Shimane (4.32/100,000 population) and Yamanashi (2.59/100,000 population) prefectures, and lowest in Ehime (0.00/100,000 population) and Yamagata (0.09/100,000 population) prefectures. The main organisations the enquirers belonged to were local governments (

conclusionDuring the COVID-19 era, we received two-thirds of technical enquiries compared with 2017-2019, because local health offices were overwhelmed by the pandemic. Since the most frequent enquiries were about diagnosis and treatment of TB, the health ministry of Japan should maintain a few specialised TB institutions with TB physicians to provide technical assistance.

Indexed as

epidemiologyTB enquiriestechnical assistancetuberculosis

Identifiers

PMID39239160
PMCPMC11373744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.